Corneal Crosslinking for Treatment of Corneal Neovascularization

Part of paid clinical trials in Indianapolis, Indiana.

Sponsor
Price Vision Group
Study ID
NCT04787471
Phase
PHASE2/PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • Corneal Neovascularization

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • 30 minute photoactivation of riboflavin 0.1% — COMBINATION_PRODUCT
    Use of riboflavin 0.1% eye drops and 3mW/cm2 UVA light for 30 minutes
  • 10 minute photoactivation of riboflavin 0.1% — COMBINATION_PRODUCT
    Use of riboflavin 0.1% eye drops and 9mW/cm2 UVA light for 10 minutes

Study Details

The study objective is to assess safety and efficacy of photo-activation of riboflavin for treatment of corneal neovascularization with or without concomitant inflammation and/or infection.

Key Dates

Start date
May 3, 2021
Status verified
Jul 2025
Primary completion
Jul 15, 2026
Completion
Sep 15, 2026

Study Design

Enrollment
62 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: 30 minute photoactivation
    photoactivation of riboflavin 0.1% using 365-nm UV light, 3mW/cm2 for 30 minutes
  • Active Comparator: 10 minute photoactivation
    photoactivation of riboflavin 0.1% using 365-nm UV light, 9mW/cm2 for 10 minutes

Primary Outcome Measure

corneal neovascularization as a proportion of the total corneal area [ Time Frame: 6 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Price Vision GroupIndianapolisIndiana46260
Marianne Price, PhD
[email protected]
317-814-2990
Francis Price, Jr., MD (PRINCIPAL_INVESTIGATOR)
Matthew Feng, MD (SUB_INVESTIGATOR)

Find similar trials in Indianapolis, IN

By research site
Price Vision Group· Indianapolis, IN